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1. Introduction
Cancer is the most frequently diagnosed disease-related cause of death among children and
adolescents [1], and malignancies involving the brain are collectively the most common solid
tumour [2, 3]. They are also either first or second in incidence overall (second only to leukae‐
mia) in the United States (USA) [1, 4,7], Canada [8], and Mexico [9]. The American Brain Tumour
Association has estimated that approximately 4,200 American children younger than age 20
would be diagnosed with a primary brain tumour in the year 2012, of whom three in four
would be under the age of 15 years [10]. However, the overall prognosis for brain malignancies
is much better in children than in adults, with up to half of paediatric brain cancer patients
surviving long-term [11]. The reason for this enhanced survival in youths is that children and
adolescents are much more likely than adults to have low-grade astrocytomas, in particular
pilocytic astrocytomas and other low-grade gliomas that are almost never fatal and often cured,
depending upon their location and surgical accessibility, rather than the grade III and IV
astrocytomas that account for the majority of tumours among adults [12-14].
Long-term survival, even in the setting of cure, is not without problems, however, with
empirical evidence accumulating that paediatric brain cancer survivors continue to suffer from
significant morbidity [15-20] and, sometimes, early death [15]. Among the more common long-
term sequelae of brain cancer and brain cancer treatment in children are seizures, which can
be quite disabling and, at times, life-threatening in themselves [15, 21-30]. In one study, seizures
were the number one predictor of disability in long-term brain cancer survivors [24, 25].
Seizures even increase a paediatric survivor’s risk of suicide into adulthood [31]. In addition,
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there is a subset of children, up to 50% [32], whose low-grade brain cancer presents as seizures
[26, 32-42]. Though the vast majority of epileptogenic tumours are supratentorial, some are
not, especially among children in whom infratentorial tumours generally comprise the
majority [43, 44], and in less typical locations like the thalamus and hypothalamus [38, 45-47].
Among thalamic tumours, for example, up to one third of paediatric patients present with
seizures [38]. As such, and because even low-grade gliomas can nonetheless be infiltrative into
high-function brain tissue [19, 48-50], while some of these lesions are totally resectable, others
are not [51-54]. This creates dilemmas as to how aggressive to be, and therefore how much risk
to take in their resection [55]. As well, the return of seizures at some distant time post-
operatively may indicate tumour growth or relapse [28, 30, 56-66], transformation into a more
aggressive lesion [28, 60, 65, 67, 68], or even the emergence of a secondary (e.g., radiation-
induced) tumour [64].
Why seizures occur in patients with brain tumours is not entirely clear [27, 69-71], and several
conjectures have been made, including alterations in regional metabolism and pH, immuno‐
logic activity, disordered neuronal function, altered vascular supply and permeability, the
release of altered tumoral amino acids, proteins and enzymes, and abnormal protein transport
and binding to receptors [27, 44, 69, 71-74]. Even genetic predispositions for tumour-related
seizures have been postulated [71, 75]. A recent excellent review of current theories and
empirical evidence on the pathogenesis of tumour-related epilepsy has been published by You
et al. [74] Discussing the relative merits of each theory is a paper in itself, and beyond the scope
of the current review.
Interestingly, tumour size has a somewhat paradoxical relationship with seizure occurrence,
in that, though the opposite is true of low-grade lesions, high-grade gliomas that present with
seizures tend to be smaller than those that present with other symptoms [76]. Moreover, high-
grade lesions that present with seizures tend to have a better prognosis than lesions of the
same size that present otherwise [77]. What this suggests is that the aggressiveness of the
tumour might have an effect upon seizure development. This being said, low-grade lesions
comprise the majority of epileptogenic tumours, both in children and adults [78]; and some
tumour types — like gangliogliomas and dysembryoplastic neuroepithelial tumours (DNET)
— are more likely to induce seizures than others [28].
In this chapter, we will thoroughly review the literature on seizures in paediatric brain cancer
patients, looking at them (1) as a presenting symptom; (2) in the early tumour management/
peri-operative period; and (3) long-term. Specific questions to be addressed in each of these
sections are: How common are they? What is their history? How do they impact patients’ lives,
both short-and long-term, and in terms of management and prognosis? How do they effect
management of the underlying tumour? How are seizures managed themselves? As much as
possible, these questions will be answered by examining empirical evidence across a number
of studies to provide, if not definitive answers, at least conclusions that are supported by
published research.
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2. Seizures as a presenting symptom of a brain tumour
2.1. How seizures present
A brain tumour is ultimately discovered in between one and three percent of children who
present with new-onset seizures [40, 42], though a slightly higher percentage has been reported
in children presenting with partial versus generalized seizures [79], and percentages as high
as 20% have been reported in children undergoing epilepsy surgery [80]. From the reverse
perspective, somewhere between 10 and 50% of brain tumours present with seizures as a
symptom [69, 74, 81-83], and sometimes as the only symptom [32, 41, 84-86], with supraten‐
torial and especially temporal lesions the most likely to be epileptogenic [44, 66, 78, 86-88]. In
one study that compared children with supra-and infratentorial tumours, for example, among
those with supratentorial lesions, 42% experienced vomiting as their first symptom, followed
by seizures in 37%, and headache in 31% [43]. Meanwhile, 62% of children with an infraten‐
torial lesion experienced headaches as their first symptom, with vomiting and ataxia account‐
ing for most of the remainder, and seizures not observed in a single case.
Because children are more likely than adults to have infra-versus supratentorial lesions, the
percentage of children presenting with seizures may be somewhat less than among adults,
closer to the 10-20% than the 30-50% range [51, 89, 90], though 50% or more has been reported
in some series [32, 35]. As in adults, of these epileptic tumours, the vast majority are supra‐
tentorial. For example, in their series of 157 children presenting to the hospital with brain
tumour-related seizures, of mean age 3.3 years, Khan et al. found that 81% of the tumours were
supratentorial and just 19% within the posterior fossa [82]. Meanwhile, Ianelli et al. reported
that 80% of their 37 paediatric patients presenting with a temporal lobe malignancy had
seizures as a presenting symptom [86]. Another excellent study on new-onset seizures
presenting in children with brain cancers was published by Shady et al. [32] who analyzed 98
paediatric brain tumour patients and found that 50% percent of the children had seizures as
part of their presentation, and 30% as their only presenting phenomenon; complex (55%) and
simple (28%) partial seizures were the most common types, accounting for more than three
quarters of all cases. Pre-operative electroencephalography (EEG) accurately lateralized to the
tumour side in 88% of the cases and to the correct lobe in 56%. In addition, tumours involving
cerebral cortex were much more likely than non-cortical lesions to present with seizures (59%
vs. 15% of patients, respectively), with temporal and frontal lobe lesions exhibiting the highest
incidence of seizures. Moreover, whereas 88% of gangliogliomas and 86% of oligoastrocytomas
were associated with seizures, seizures were noted in just 21% of the patients with an anaplastic
astrocytoma. Finally, as described elsewhere [32, 77], patients with seizures at presentation
had a better prognosis than those without (p=0.02) [32].
Virtually every possible tumour type has been reported presenting as seizures, especially low-
grade gliomas [27, 30, 32, 34, 37, 39, 70-72, 75, 76, 78, 91-93] and glioneuronal tumours like
ganglioglioma and dysembryoplastic neuroepithelial tumour [28, 44, 62, 73, 88, 89, 91, 94, 95];
but including oligodendroglioma [77, 96, 97], cortical ependymoma [98], medulloblastoma
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[47], subependymal giant cell astrocytoma (SEGA) [99], meningioma [10]0, thalamic and
cerebellar glioma [38, 46], and a variety of atypical, systemic and metastatic tumours, like
primary meningeal osteosarcoma [84], acute lymphoblastic leukemia [101], anaplastic large
cell lymphoma [102], neuroblastoma [103], melanoma [104], various sarcomas [105, 106],
Ewing’s sarcoma [107], malignant germ cell tumours [108], and others [16, 109].
There is no stereotypical seizure presenting as an early symptom of a brain tumour. Early
seizures may be generalized, simple partial, complex partial, or mixed, depending upon the
tumour’s size, location, level of aggressiveness, and other factors [24, 26, 27, 33, 34, 37, 70, 74,
77, 82, 87, 110-115]. This being said, among children, seizures as a presenting symptom of brain
tumour are most commonly complex or simple partial, versus generalized, with complex
partial seizures generally accounting for from 50% to as high as 85% of all new-onset seizures
[32, 63, 69, 86, 115-117]. The lone series in which this was not true was that reported by Hirsch
et al., in which complex and simple partial seizures together only accounted for half of all cases
[118]. The percentages generally reported for children and adolescents are somewhat different
than for adults, in whom tumour-associated seizures tend to be more evenly distributed across
the four most typical seizure types [58]. Other atypical and, therefore, less well recognized
forms of seizure have been described in children as well, including gelastic seizures, charac‐
terized by uncontrolled fits of inappropriate laughter [45], tics and Tourrette-like symptoms
[119], and sympathetic storms in a 7-year old with a midbrain glioma [120]. In addition,
especially in the paediatric population, tumors may arise in the setting of a variety of familial
syndromes such as neurofibromatosis types 1 [121] and 2 [122], and tuberous sclerosis [123].
Seizures in these conditions are often blong-standing, frequent, and intractable because of the
numerous non-neoplastic lesions that can involve the CNS [55, 124, 125]. In such patients, the
diagnosis of a new neoplastic lesion can be especially challenging [124, 126].
The diagnosis of brain tumour does not always quickly follow the onset of seizures. In one
study reported by Ibrahim et al., for example, the time from seizure onset to tumour diagnosis
among ten children presenting with seizures ranged from two weeks to two years, averaging
six months [37]. A wide range of opinions and practices exist regarding how aggressive to
pursue diagnostic imaging in children presenting with seizures [36, 41, 51, 79, 80, 100, 127-133].
For example, in one series of eighteen patients between the ages of 1 month and 13 years who
presented with seizures and were discovered to have DNETs between January 1992 and
December 2004, the preoperative evaluation included magnetic resonance (MR) imaging and
interictal scalp electro-encephalography (EEG) in all patients, but functional MR imaging also
was performed in eight patients, video monitoring with scalp EEG during seizures in 12
patients, interictal single-photon emission computerized tomography (SPECT) scanning in one
patient, and ictal SPECT scanning in two patients [132]. Meanwhile, in their 2010 review of
eleven clinical trials for anti-epileptic drugs (AEDs) conducted over the preceding two years,
Jansky et al. noted that none of the trials required MRI as part of the patient enrollment protocol
[128]. Increasingly, with advances in imaging and the recognition that the resection of
epileptogenic lesions is both safe and effective for many patients, there seems to be growing
opinion that the initial work-up of new-onset non-febrile seizures in children should include
Molecular Considerations and Evolving Surgical Management Issues in the Treatment of Patients with a Brain Tumor200
both an EEG and MRI, despite the likelihood that the majority of imaging studies will be either
normal or inconclusive [134, 135]. As discussed in the next section, mounting evidence suggests
that new-onset seizures in the setting of a tumour, and conversely, tumours in the setting of
new-onset seizures both have therapeutic and prognostic implications.
2.2. Implications of brain-tumour induced seizures
Having a child’s brain tumour present as seizures adds therapeutic complexity with respect
to how the patient is initially managed, since peri-operative control of seizures is obviously
considered of extreme clinical importance. The type of seizure a patient has also may have
prognostic significance, both in terms of patient survival [65, 136] and how easily the seizures
are controlled with anti-epilepsy drugs (AED), both peri-operatively and long-term. How well
AEDs work, in turn, may have implications relating to how aggressive surgical resection
should be.
Although no reliable data have been published for children, adults who present with seizures
as their sole symptom tend to have less aggressive or advanced lesions than those who present
with symptoms or signs of increased intracranial pressure like papilloedema, headaches [65],
neurological or cognitive deficits [65, 136]. Although this intrinsically makes sense — the fewer
the symptoms, the less aggressive or advanced the disease — extrapolating these findings to
children must be done with caution, because a disproportionate number of paediatric lesions
tend to be brainstem tumours that, though usually low-grade and non-epileptogenic, often are
non-resectable because of their location and proximity to function-rich neural tissue [2, 3,
137-139]. Nonetheless, especially among supratentorial lesions, it makes sense that having
seizures present before all other symptoms develop is a hopeful prognostic sign, given that
low-grade gliomas and other so-called benign lesions tend to be associated with much higher
seizure rates than high-grade lesions [32, 87, 91, 113, 140, 141].
Having seizures in the presence of a tumour has implications with respect to management of
the seizures as well, in that studies have shown that such seizures tend to be more resistant to
AEDs than idiopathic seizures [133, 142]. This appears to be especially true for patients who
present with a history of numerous seizures [142]. This likelihood of drug resistance, which has
been formally defined as “the failure of adequate trials of two tolerated, appropriately-chosen and
used antiepileptic drug schedules (whether as monotherapies or in combination) to achieve sustained
seizure freedom” [143], may play a role in determining the aggressiveness of surgery for tumour
resection. For example, given the clear superiority of epilepsy surgery over medical manage‐
ment alone, in terms of achieving freedom from seizures in patients with intractable seizures
(65% vs. 8% in one relatively recent meta-analysis [144]), a decision might be made to pursue
more aggressive resection in a patient with repeated new-onset seizures upon initial work-up
of seizures and diagnosis of their brain tumour, versus the patient who presents with a single
seizure prior to tumour detection. Moreover, for many epileptogenic lesions, surgical resection
often leads to either complete resolution of seizures, sometimes without the need for continued
AEDs, or to a marked reduction in their frequency, as will be elaborated upon next.
Seizures in Children with Brain Tumours — Epidemiology, Significance, Management, and Outcomes
http://dx.doi.org/10.5772/58961
201
2.3. General principles of management
How tumor-induced seizures are managed largely depends upon the aggressiveness and
location, and therefore, the prognosis of the underlying tumour. In patients with invariably
terminal forms of cancer, including primary brain neoplasms like glioblastoma multiforme
(GBM), and metastatic spread to brain, the goal usually is to prolong life over months to, at
most, a few years, while preserving as high a quality of life as possible. In both adult and
paediatric patients with high-grade astrocytomas like GBM, even partial resection of terminal
lesions has been shown both to prolong life and reduce the frequency and severity of seizures
[145-147]. Clearly, such surgery needs to be performed as soon after diagnosis of the lesion as
possible to have any effect upon outcome. Such is not the case in many patients with low-grade
tumours like stage I and II gliomas and gangliogliomas, in whom progression of the tumour
may be so slow as to be virtually undetectable, and patients can live for years without apparent
disease progression, so that any decision to surgically remove the offending lesion may be
delayed for years [58, 93, 148, 149]. This being said, there has been increasing emphasis on
surgically resecting low-grade tumours early in the course of disease [131] for a multiplicity
of reasons. Among these reasons are that anywhere from 20% to roughly one third of low-
grade gliomas (LGG) fail to respond to anti-epileptic medications [72, 150], and many that do
respond require more than a single AED [150], placing patients, and especially children, at risk
for long-term drug toxicities [23, 24, 59, 71, 151-153]. Among the various documented toxicities
of AEDs are wide-ranging adverse effects on cognitive function [23, 153], which already may
be impaired because of the tumour itself and the radiation therapy sometimes administered
to treat it [18, 20, 154-156]. Moreover, surgical resection of LGG has been shown to enhance
long-term survival [19] and to significantly improve the likelihood of seizure control [27, 70].
Though the data are not definitive, there is some evidence suggesting that, among the various
seizure types, partial seizures, either simple or complex, may be less likely to respond to anti-
epileptic drugs than generalized or mixed seizures [93, 157, 158]. This resistance may be noted
initially, so that seizure control is never achieved; but it also may develop over time, so that
seizure control is lost and never regained [158, 159]. In such patients, therefore, there may even
be an increased incentive to pursue surgical resection of the tumour+/-any adjacent epilepto‐
genic foci, if the lesion can be accessed with no undue risk.
Several studies have shown that radical removal of an epileptogenic brain tumour is a strong,
and likely the strongest, predictor of seizure freedom [127]. However, additional predictors
include the type of seizure, the histopathology of the tumour, the age of the patient at the time
of surgery, and the duration of epilepsy [127]. Among the various tumour histologies, tumours
that are non-resectable due to infiltration, like high-grade astrocytomas, can be problematic
over the patient’s relatively brief period of survival [160]. However, as stated earlier, such high-
grade lesions tend to be less often epileptogenic than their low-grade counterparts [32, 87, 91,
113, 140, 141]. In long-term brain cancer survivors, glioneuronal tumours, and particularly
low-grade gliomas, gangliogliomas and dysembryoplastic neuroepithelial tumours (DNETs),
often produce quite drug-resistant epilepsy in children, so that complete surgical resection of
the tumour is typically considered the primary focus of treatment [28, 61-63, 88, 94, 116, 132].
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In such patients, post-operative seizure-freedom rates often approach or exceed 80% [35, 48,
51, 58, 66, 86, 88, 90, 93, 115, 157, 161-169].
Traditionally, there has been some concern about being too aggressive with younger children
with brain tumours, because of the risk of long-term adverse effects on neurological develop‐
ment, the risk of secondary neoplasms, and other neurological sequelae [155]. That such risks
exist is certainly true of radiation therapy [18, 20, 64, 153-156], but it also is true of surgery [170].
However, recent studies have shown that surgery to resect epileptogenic brain tumours is both
effective and safe for the vast majority of infants and toddlers [35, 55, 171]. In one large survey,
for example, data were collected retrospectively on 116 patients less than 3-years old from
eight centers across Canada from January 1987 to September 2005 who had undergone epilepsy
surgery [171]. Among the various seizure aetiologies were malformations of cortical develop‐
ment (n=57), tumours (22), Sturge-Weber syndrome (19), and infarcts (8), with 10 cases either
of unknown or some other cause. Seizure onset was in the first year of life in 82%, and the
mean age at the time of the initial surgery was 15.8 months (range: 1-35 months). Second
surgeries were performed in 27 patients, with six patients requiring a third surgical procedure.
Among the initial 116 procedures performed were 40 hemispheric operations, 33 cortical
resections, 35 lesionectomies, 7 temporal lobectomies, and one callosotomy. Of the 151
operations, including the 27 second and six third procedures, only one resulted in a surgery-
related death. The most common surgical complications were infection, in 17 patients, and
aseptic meningitis in 13. Of 107 patients assessed more than one year postoperatively, 72
(67.3%) were seizure free (Engel I), 15(14%) had experienced at least a 90% reduction in seizures
(Engel II), and 12 had at least a 50% reduction (Engel III), with only eight exhibiting no benefit
(Engel IV). Moreover, 55.3% of the children exhibited signs of improved development post-
operatively [171].
Consequently, regardless of patient age, the focus for most patients with low-grade lesions has
become, whenever possible without the undue risk of peri-operative death or long-term
adverse neurological sequelae, to attempt total or at least subtotal tumor resection earlier rather
than later in the course of disease. Debate rages, however, as to how aggressive to be achieving
this goal, whether or not resecting the lesion alone is enough, and what intra-operative
technologies to use to aid in identifying tumour margins and other epileptogenic foci.
Moreover, not all patients will be eligible for surgery and will have to rely on non-neurosur‐
gical treatments alone, most notably anti-epileptic drugs (AEDs) and radiation therapy. The
next section briefly discusses the benefits, risks and utilization of AEDs both prior to and in
lieu of surgery.
3. Anti-Epileptic Drugs (AEDs)
An extensive review paper could be written discussing the various advantages and disadvan‐
tages, indications and contra-indications, and drug-drug interactions that exist for the
extensive list of anti-epileptic drugs that now are available for use in patients with brain
tumour-induced epilepsy, all of which is beyond the scope of the current review. Here, we
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briefly describe the roles of AEDs, both in prophylaxis against and control of tumour-induced
seizures, some of the risks of prolonged use, and at least the theoretical advantages of the new
class of non-enzyme inducing drugs.
3.1. AEDs for seizure prophylaxis
In three recent surveys of neurosurgeons, including one survey specifically of members of the
American Association of Neurologic Surgeons (AANS), the majority (up to 70%) of respondents
reported prophylactically initiating AEDs in brain tumour patients who had not yet experi‐
enced a seizure [172-174]. This practice of prescribing AEDs prophylactically in brain tumour
patients with no seizure history persists, even though empirical evidence addressing this
practice is inconclusive at best [78, 81, 127, 140, 172]. Moreover, many authors and the most
current American Association of Neurology practice parameters argue against it [113, 140, 172,
175, 176]. The argument of AED detractors is that both meta-analyses published since 2000 to
address this issue failed to provide sufficient evidence to promote their prophylactic use in
brain-tumour patients without seizures [173, 177]. The first meta-analysis, published in 2000
by Glantz et al. [173], analyzed 12 studies, of which four were randomized controlled trials
and eight were considered to be “well-designed observational studies with concurrent
controls”, sufficient to be classified as class II evidence. Not one of these twelve studies
demonstrated a statistical advantage of the AED being studied (phenytoin, depakote, or
phenobarbital) over placebo [173]. The second, somewhat more stringent meta-analysis,
published in 2004 by Sirven et al [177], only included five RCTs, assessing the prophylactic use
of either phenobarbital, phenytoin, or valproic acid. Of the five trials, four identified no
statistical benefit of AED use for peri-operative seizure prophylaxis. The one exception was a
1983 study published by North et al [178], in which not only patients with brain tumours, but
patients who had undergone craniotomies for aneurisms and head injuries were included. A
closer, empirical look at these data reveals no advantage at all when brain tumours are
considered alone: seizures occurred in 9/42 on phenytoin, and in 5/39 on placebo (OR=1.11,
95% CI=0.58, 2.12). Further considering just those patients with glial tumours (versus menin‐
giomas, sellar tumours, and metastases), seizures occurred in three of 16 on phenytoin versus
just one of 16 on placebo (1.15; 0.42, 3.19) [178]. Overall meta-analysis across the five RCT
confirmed the lack of any AED benefit at both one week (OR, 0.91; 95% confidence interval
[CI], 0.45-1.83) and six months (OR, 1.01; 95% CI, 0.51-1.98) of follow-up. The AEDs also
exhibited no effect on seizure prevention for specific tumours, including primary glial tumors
(OR, 3.46; 95% CI, 0.32-37.47), cerebral metastases (OR, 2.50; 95% CI, 0.25-24.72), and menin‐
giomas (OR, 0.62; 95% CI, 0.10-3.85) [177].
More recently, in a review published in 2011, Kargiotis et al. non-statistically examined
published evidence on more currently-used AED, including the newer non-enzyme inducing
drugs, and concluded that, among patients with either brain metastases or primary brain
tumors who have never experienced seizures, prophylactic anticonvulsant treatment might be
justified, but only for up to six months postoperatively after surgical excision of the cerebral
tumour, since most of these patients will never experience seizures, and the anti-epileptic
drugs may cause toxicity and adverse interactions with chemotherapeutic treatments admin‐
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istered to control the neoplasm itself [109]. For such prophylaxis, the authors argued that newer
antiepileptic drugs like levetiracetam and oxcarbazepine are preferable to older agents like
phenytoin and carbamazepine [109]. To date, however, no hard evidence supports any of these
recommendations, and certainly not in children.
In a study by Hardesty et al., only 7.4% of 223 paediatric patients with brain tumours but no
history of seizures experienced even a single seizure during their surgical admission, even
though only 4.4% of patients had been started on a prophylactic AED [179]. This percentage
is similar to the 8.0% observed among those on placebo in a controlled study in which 127
patients awaiting brain tumour surgery, ranging in age from 16 to 84 years, were randomized
to receive either phenytoin 15mg/kg intravenously in the operating room, followed by 100 mg
three times daily, either by mouth or intravenously, for seven days or placebo [180]. Thereafter,
the dose of each was tapered. The 30-day incidence of seizures actually was higher in the
phenytoin group (10.0%) than in controls (8.0%), albeit not statistically so. Moreover, the rate
of complications was 18.0% versus 0% in the treatment versus placebo group, respectively (p
< 0.001).
In the Hardesty study on youths [179], dependent factors associated with peri-operative
seizures included a supratentorial tumour, patient age less than two years, and the presence
of post-operative hyponatraemia due to either the syndrome of inappropriate antidiuretic
hormone (SIADH) or cerebral salt wasting. No other factor was independently predictive of
incident seizures, including tumour type, the lobe of the brain affected, the amount of operative
blood loss, and the length of surgery [179]. Consequently, though children and adolescents
who are awaiting brain-tumour resection and have recurrent seizures might warrant the
initiation of an AED pre-operatively, and perhaps also children under age two years with a
supratentorial tumour and those with highly-epileptogenic tumours like DNETs, even in the
absence of seizures, the prophylactic use of these drugs is far from empirically justified. What
is more prudent is to monitor all patients carefully throughout the peri-operative period to
identify clinical factors that might place the child at risk, like electrolyte imbalances and fever.
3.2. AEDs for seizure control
Although in some small series of patients, seizures have been found to occur in up to 50%
of  paediatric  patients  with  a  brain  tumour  [170],  in  most  populations,  the  overall  inci‐
dence of seizures in this patient population is considerably lower, in the 10-20% range [51,
89, 90]. This is largely due to the infratentorial location of the majority of paediatric tumours,
where  very  few are  epileptogenic  [37].  As  such,  only  a  small  minority  of  children  and
adolescents with a brain tumour will likely ever require an AED, and almost all will have
a supratentorial lesion. For example, from a database of 334 patients up to 21-years old,
Sogawa et al. only identified 32 (10%) who had been started on an AED [83]; 94% of these
32 tumours were supratentorial, and 78% were glial [83]. Similarly, in their series of 280
patients between the ages of two months and 18 years of age, Khan et al. identified only
55 (20%) patients who had required an AED, among whom 49 (89%) had a supratentorial
lesion [90]. This being said, over a 20-year period at a single institution, Khan et al. followed
157 patients  who had presented with seizures and a brain tumour during childhood or
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adolescence, all of whom had been on at least one AED at some point [82]. Of these patients,
phenytoin was the first AED used for 52 patients, carbamazepine for 38 patients, gabapen‐
tin for 31, and phenobarbitol for 14. Sixty-two of these patients ultimately were taken off
all AEDs; but 17 of these 62 (27%) suffered seizure recurrence [181].
DNETs and gangliogliomas, which typically become manifest during childhood, adolescence
or young adulthood, represent only a small percentage of CNS tumours in either youths or
adults [6]. However, these tumours are almost always associated with seizures. Consequently,
they comprise a disproportionate percentage of tumour-associated epilepsy cases [28, 44, 62,
73, 88, 89, 91, 94, 95]. Moreover, DNETs tend to be extremely resistant to AED therapy [62,
182-186]. Consequently, though AEDs generally are initiated in such patients, the majority
ultimately will require surgical resection.
There is virtually no debate that AEDs are of use in treating brain tumour patients with
seizures, in patients with repeated seizures awaiting surgery, in patients in whom tumour
resection is infeasible, and in those whose seizures remain refractory despite surgery. How‐
ever, there is concern about the risks of their long-term use, especially in patients who require
on-going chemotherapy for their brain malignancy due to drug interactions and mutually-
shared toxicities [81, 83, 127, 140, 151, 159, 172, 176], 187]; and significant debate regarding
when and how AEDs should be discontinued post-operatively.
One of the biggest issues relating to AEDs is their potential interactions with anti-neoplastic
drugs administered to control tumours and prolong survival. In a paper reviewing anti-
epileptic drugs, Kargiotis et al. [109] listed 25 chemotherapeutic medications that interact with
AEDs, most commonly carbamazepine, phenobarbitol, phenytoin and primidone, but also
valproic acid. Common interactions are the AED accelerating metabolism of the chemothera‐
peutic drug, and the chemotherapeutic drug reducing serum levels of the AED [109], two
results that potentially accentuate each other — when AED levels fall, AED doses must be
increased to achieve seizure control, which will further increase metabolism of the chemo‐
therapeutic drug, resulting in its doses needing to be increased, and so on. Included on their
list of 25 drugs were 13 drugs often selected for the treatment of brain metastases, as well as
nine drugs currently used to treat glioblastomas, six drugs to treat medulloblastomas, and five
to treat malignant meningiomas.
In the current paper, Table 1 lists these interactions in reverse, indicating those anti-neoplastic
drugs used for CNS malignancies that have had documented interactions with each of the five
AEDs listed above. What is clear from this table is that all but valproic acid interacts with
almost all of the chemo-therapeutic drugs typically used for CNS cancers.
The only drug on the list published by Kargiotis et al. [109] this is not considered to interact
with AEDs is temozolomide (TMZ), a less toxic and more-easily tolerated orally-adminis‐
tered drug that effectively crosses the blood-brain barrier [188] and is now commonly used
for both high-grade [189] and low-grade [190, 191] gliomas, as well as for brain metasta‐
ses  [192]  and  melanomas,  often  in  combination  with  radiation  therapy.  There  also  is
evidence that TMZ itself reduces the frequency of seizures, independent of AED dose. In
one study in which 39 patients receiving TMZ (mean age 46.0 years) were followed for a
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mean 39 months and compared with 30 patients not on TMZ (mean age 41.5 years), patients
on TMZ experienced a 59% reduction in seizure frequency versus just 13% in controls (p
< 0.001) [150]. However, for reasons that are not entirely understood, TMZ appears to be
less  effective  in  children [193].  For  this  reason,  other  anti-neoplastic  drugs  typically  are
prescribed in children and adolescents,  particularly multiple-drug regimens that  include
carboplatin and vincristine [193-195], two drugs both documented to interact with the older,
cytochrome P450-inducing anti-eptileptics [109] (Table 1).
Meanwhile, evidence continues to mount documenting both the effectiveness and safety of
newer-generation AEDS, like levetiracetam, oxcarbazepine and pregabalin [152, 196-204].
Though direct comparisons against the older drugs are generally lacking, theoretical advan‐
tages include the lack of any effect on cytochrome P450, and the fact that these drugs generally
target specific risk factors for tumour-induced seizures [81]. Recently, in a survey of 32
paediatric brain-tumour patients requiring AEDs for seizure control, Sogawa et al. found that
patients who had been started on any the newer–generation drugs (levetiracetam, oxcarbaze‐
pine and lamotrigine) were three times as likely to remain on these drugs than those started
on one of the older drugs like valproic acid, phenytoin, and phenobarbitol (73% vs. 28%,
respectively, p=0.04) [83]. Although the sample was small, there also was evidence of increased
toxicity with the older drugs, with five versus just two adverse events resulting in drug
discontinuation [83].
Of course, the treatment of brain tumours is anything but a static field. In attempts to reduce
tumour progression and prolong survival, newer chemotherapeutic drugs are continuously
being tested. Some, like nimotuzumab [205]and bevacizumab [206], both of them antibodies
against epithelial growth factor receptors (EGFR), have been demonstrating considerable
promise, and this may have implications for which AEDs are best tolerated as interactions and
mutual toxicities become clearer. What is evident is that AEDs, in themselves, are usually
inadequate to control seizures in most patients with epileptogenic brain tumours. And while
novel treatments like stereotactic radiosurgery [154], vagus nerve stimulation [207], and
ionizing radiation [208] are emerging, at this time optimal management of a child or adolescent
with epilepsy caused by a brain tumour almost always necessitates resection of the lesion itself.
4. Surgical resection of epileptogenic brain tumours
4.1. The benefits and risks of surgery
In recent years, there has been a trend towards earlier surgical intervention in young patients
with low-grade epileptogenic tumours; but is this justified? One potential justification is the
risk of malignant transformation of low-grade tumours which, even though uncommon, has
been described for virtually all tumour types and often is catastrophic [60, 64, 65, 67, 68, 97,
112, 131, 209-213]. A second justification pertains to improved seizure control and the de‐
creased reliance on AEDs, with some patients potentially able to discontinue anti-epileptic
medications altogether59, [61, 181, 185]. But how successful is tumour resection in terms of
controlling or eliminating seizures?
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Table 2 lists 26 studies [35, 51, [61-63, 86, 90, 94, 96, 132, 148, 149, 168, 182, 184, 185, 214-223]
published over the past two decades in which seizure outcomes in children and adolescents
undergoing surgery to remove epileptogenic brain neoplasms were examined. Across these
26 studies are 741 patients, ranging in age from one month to 21 years of age, with a mean age
of 9.1 years and a mean duration of post-operative follow-up of more than four years (overall
mean=52 months, with individual study means ranging from 12 to 148 months). Though one
study [86] included six paediatric patients with high-grade gliomas (either GBM or grade III
astrocytoma), and another indicated 11 patients with either grade III or grade IV lesions [35],
almost all of the remaining 724 patients had low-grade (grade I or II) lesions, including various
low-grade gliomas and glioneuronal tumours, and less typically epileptogenic tumours like
craniopharyngiomas and a dysplastic cyst. Spanning these studies, surgical approaches clearly
differed, with some surgeons either largely or exclusively performing lesionectomies alone,
others performing further procedures like partial lobectomies [86, 148] and amygdylohypo‐
campectomies [182], and still others using various intra-operative mapping technologies like
electrocortography (ECoG) [63, 132, 184, 214] to identify and ultimately resect extra-tumoral
epileptogenic tissue. However, the ubiquitous goal was total tumour resection, whenever
possible, an objective that was achieved in roughly two-thirds of cases.
Overall, the series with the lowest total resection rates were those that included a number of
oligodendrogliomas (ODG), with resection rates ranging from 30% in a study exclusively of
ODG and ODG-mixed lesions [96] and 40% in an older study in which half the patients had
ODG [219], to 58% and 61% in studies in which the proportion of ODG was considerably lower
[90, 220]. This discovery is not unexpected, given the highly infiltrative nature of these tumours
[77, 96, 97, 191].
The outcomes of surgery otherwise were impressive, with almost four out of every five patients
(77.7%) seizure free at the time of the final follow-up assessment, and 92.6% experiencing a
significant improvement in their seizures from baseline, to Engel class 1, 2 or 3. Examining
these data further reveals moderately strong, borderline statistically-significant correlations
between the percentage of total resections achieved within any given series and the rate of
seizure freedom (r=0.37, p=0.08), and between the percentage of total resections and the
percentage of patients whose seizures were improved post-operatively (r=0.36, p=0.09).
However, no correlation is apparent between the duration of follow-up and either outcome
(r=0.06, p=0.78 and r=0.26, p=0.22, respectively), suggesting that it was the surgical procedure,
rather than post-operative management, that influenced seizure outcomes.
There also were no peri-operative deaths among the 741 patients, some of whom even
underwent second procedures to resect residual tumour detected by imaging after the first
procedure. The overall operative complication rate, adjusted for missing data, was 11.7%, with
the vast majority of complications and new neurological deficits transient and completely
resolved within weeks to months of the procedure. As stated above, a small number of patients
required repeat surgeries to achieve seizure control, sometimes associated with total tumour
resection. For example, in one series a second surgery was required in three of 29 paediatric
patients with supratentorial gangliogliomas, and all became seizure free after the second
operation [216].
The studies by Jo et al. [223] and Gaggero et al. [35] are of special note because all the patients
were infants, under the age of 5 and 3 years, respectively. In the first small series of 14 patients
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of mean age 2.7 years (32 months) [223], total resection of the epileptogenic lesion was achieved
in 71%, as was total seizure freedom an average of 35 months post-operatively. In addition, all
14 infants experienced a significant reduction in seizure frequency, either being totally seizure
free or having seizures limited to auras alone [223]. There also were no deaths and no reported
operative complications. In the second study, which included 20 infants under age 3 years
(mean age 1.5 years), eleven of the 20 children had either a grade III or grade IV neoplasm,
including four choroid plexus carcinomas, one anaplastic oligodendroglioma, one anaplastic
ependymoma, one immature teratoma, two glioblastoma multiforme, one PNET and one
neuroblastoma [35]. Despite this, total resection was achieved in 70% of the children, seizure
freedom beyond four years in 55%, and seizure improvement in 90%. Interestingly, all 20
patients lived beyond four years, and 17 remained alive at eight years of follow-up [35]. These
two studies that imply both the effectiveness and safety of aggressive brain tumour resection
in infants is counter to another study on 18 infants under one year of age who had a variety of
grade I through IV lesions [170]. In this series, there was only one peri-operative death, due to
massive brain haemorrhage in an 8-month old child with a deep, right parieto-occipital
ganglioglioma. However, three patients had new-onset seizures following surgery, and an
additional three had worsened neurological deficits. Of the nine patients who had pre-
operative seizures, three improved, five did not improve, and one died. Overall, as of the
paper’s publication, only eight of the twenty patients had survived beyond infancy, with five
now into adulthood (ages 18 – 26) [170]; two of the adult survivors were severely disabled at
the time of the report, both having a Karnofsky score [224] of just 40%.
Also worth noting from Table 2 are the six studies in which only patients with dysembryo‐
plastic neuroepithelial tumours (DNETs) were included (Table 3) [61, 62, 94, 132, 182, 184].
These six studies encompass 132 patients, of mean age 9.7 years, amongst whom total tumour
resection was achieved in almost 82%, seizure freedom in 87%, and seizure improvement in
all but a single patient (99%). However, the adjusted surgical complication rate was slightly
higher than that noted across all 26 studies.
Table 4 lists four additional studies of note. Among these four additional studies, three were
excluded from the previous table and its summation totals because vascular and other non-
neoplastic lesions were intermingled with non-vascular lesions, with no data provided to
distinguish between them; and the fourth was excluded because all the patients had tuberous
sclerosis, in which brain tubors often cause uncontrolled seizures [225, 226]. The fifteen patients
in this fourth study all had subependymal giant cell astrocytomas (SEGA), a tumour that is
found in between five and fifteen percent of TS patients [123], typically developing in the
region of the foramen of Monro, where it frequently causes obstructive hydrocephalus.
Seizures primarily result from a broad array of intra-cerebral tumors, which include the cortical
tubers mentioned above, and subependymal nodules, in addition to SEGA [225, 226]. The long-
term prognosis therefore is poor, with death primarily resulting from intractable seizures or
SEGA-induced obstructive hydrocephalus [225, 226]. As such, it is not unexpected that Cuccia
et al. [99] failed to achieve either seizure freedom or any meaningful clinical improvement in
seizure frequency in any of their patients. The inherent complexities of SEGA removal, given
the relative inaccessibility of these tumours, also could account for the high complication rate
(6 of 15, 40%).
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The three remaining studies [117, 227, 228] involved a high proportion of non-neoplastic
lesions that were not analyzed distinctly from neoplastic cases. Mean seizure free rates across
the three studies ranged from a low of 56% to a high of 81%, with seizure improvement noted
in 81.3% and 92.4% in the two studies in which this outcome was reported [117, 227]. Although
no deaths were reported, almost one in four patients (73 of 320, 22.8%) had a significant post-
operative complication, likely due to the highly vascular nature of many of the lesions and the
increased risk of intracranial bleeding.
4.2. Post-operative management
According to the 30 studies (26+4) analysed above, the rate of post-operative complications
among patients with epileptogenic brain tumours is low, likely somewhere between 10 and
20 percent, depending upon the nature of the tumour resected, its location, and perhaps other
factors as well. The risk of peri-operative mortality also appears to be exceedingly low, with
not a single surgery-related death reported among those 873 patients.
Few papers have been published on the post-operative management of paediatric brain
tumour patients. What has been reported is that youths tend to experience different intra-
operative and post-operative complications than adults, and that these complications affect
both short and long-term outcomes, including disability, mortality and hospital and PICU
lengths of stay and, hence, direct health care costs [229, 230]. Among the various risk factors
for complications are fluid and electrolyte imbalances, which may be especially significant in
children. One also must consider that volume of blood loss is all relative to the age and size of
the child, given that a human’s total blood volume varies dramatically relative to their age and
size: falling from roughly 85 to 90 ml per kg in term neonates, to roughly 85 ml/kg in infants,
80 ml/kg in children under age 10, 70-75 ml in children > 10 and adolescents, and 70ml/kg in
adults [231, 232]. Clearly then, 100 ml of blood loss may mean nothing to an adult, but may
represent 25% or more of the total blood volume of a newborn.
In general, the most common fluid and electrolyte abnormalities observed after brain surgery
in children relate to serum sodium levels, with hyponatraemia secondary to either the
syndrome of inappropriate diuretic hormone (SIADH) secretion or cerebral salt wasting
syndrome, and hypernatraemia caused by diabetes insipidis (DI) [233-236]. In one series of 79
children, for example, water and sodium disorders were noted in 36 (46%): 23 (29%) with DI,
12 (15%) with SIADH, and a single patient with cerebral salt wasting [236]. Why this is
especially important in the paediatric patient in whom an epileptogenic brain tumour has been
resected is that sodium disturbances are a significant risk factor for seizures. In one study
involving 223 paediatric patients with epileptic brain tumours undergoing 229 surgical
procedures, post-operative hyponatraemia — due to either SIADH or cerebral salt wasting —
was one of just three independent factors associated with peri-operative seizures, the other
two being a supratentorial tumour and patient age less than two years [179].
In another study of 105 paediatric patients post brain tumor resection admitted to the PICU,
patients required an average of 0.7 unexpected intensive care unit interventions, mostly
secondary to sodium abnormalities, followed by new neurologic deficits, paresis, and seizures
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[237]. Interestingly, however, 68% of the patients were stable enough to be transferred out of
the PICI within 24 hours of surgery.
With respect to anti-epileptic drugs, the same applies post-operatively as pre-operatively, in
that there is generally no need to initiate AEDs in patients who have not yet experienced
seizures, given the lack of evidence documenting any benefit of prophylaxis [180, 238]. This
being said, there are no clear guidelines as to when and how to discontinue AEDs if they have
been initiated pre-operatively, and there is always the potential risk of withdrawal-induced
seizures [59]. In one study of 332 mostly adult patients, but including some as young as age
16, among those with AEDs that had been initiated to treat seizures pre-operatively, patients
with a longer history of seizures (p<0.001) and those with simple partial seizures (p=0.004)
were found to be especially likely to continue to have seizures in the immediate post-operative
period, as well as poorer control long-term [58]. If AEDs are started post-operatively to reduce
the risk of seizures following the trauma of surgery in a patient who otherwise has not had
seizures, they generally should be administered short-term [239].
5. When seizures persist or recur
In virtually every series we have reviewed, patients were described who underwent resection
of their epileptogenic brain tumour, with apparently successful removal of the tumour, yet no
achieved control of seizures. Additional patients were noted to suffer from the post-operative
onset of new seizures [170]. And still others had complete control of their seizures, only to
relapse later, either while still on an anti-epileptic drug or after all AEDs had been withdrawn.
Each of these three scenarios has implications with respect to patient prognosis and manage‐
ment.
5.1. Implications of post-operative seizures
The clinical implications of seizures that either start or re-start months or years after the initial
resection of tumour are somewhat different than seizures that start immediately post-
operatively or that started pre-operatively and failed to resolve with surgery. The major
concern with the latter two scenarios is that tumour resection either was incomplete, or that
extra-tumoral epileptogenic tissue was not removed. Over the years, attempts have been made
to optimize the resection of epileptogenic lesions by both better delineating their margins and
identifying extra-tumoral epileptogenic tissue, using intra-operative tools like electrocorti‐
cography (ECoG) to identify potential seizure-inducing tissue irregularities like cortical
dysplasia [63, 77, 93, 132, 1 [6]3, 184, 214, 216, 240, 241]. This has led to debate regarding the
relative benefits and safety of performing epilepsy surgery rather than just lesionectomies in
patients with tumour-triggered seizures [242]; though, in fact, many surgeons have been
utilizing additional surgical steps like lobectomies, amygdylohypocampectomies and, in
extreme cases, hemispherectomies for decades [63, 86, 94, 117, 132, 148, 149, 168, 182, 185, 214,
217, 218, 222, 227, 243]. To date, almost no direct empirical comparisons have been undertaken.
In perhaps the most methodologically sound study, Gelinas et al. retrospectively compared
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34 patients who underwent ECoG-aided epilepsy surgery and 33 patients who had undergone
simple lesionectomies without ECoG, all between the ages of 3 months and 16 years, in
Vancouver, Canada [214]. One year post-operatively, the two treatment arms were virtually
identical, with roughly 80% of patients in each group seizure free. However, at a mean follow-
up of 5.8 years, there was a trend towards improved seizure freedom in patients in the ECoG
group, with 79% versus 61% patients still seizure free (p=0.08). The investigators also noted
no increase in neurological morbidity among patients who had undergone the more extensive
ECoG-guided cortical resection, and that these patients were less likely to require repeat
epilepsy surgery [214]. Why this has implications post-operatively relates to the potential need
for re-operation, as discussed in the next section.
If the major concern of continued seizures is residual tumour or other epileptogenic tissue, the
major concerns with later tumour recurrence are multiple. They include the possibility: (1) that
the tumour itself is re-growing, having never been fully resected; (2) that the tumour has
undergone malignant transformation; or (3) that some secondary tumour has started to
develop, perhaps as a consequence of brain irradiation, chemotherapy, or some other cause.
The risk of second brain malignancies is especially high in patients with CNS tumour-
associated familial syndromes like neurofibromatosis types 1 [121] and 2 [122], tuberous
sclerosis [123], von Hippel Lindau disease [244, 245], and basal cell nevus syndrome [246], with
some of these tumours originating within the brain and others the result of metastatic spread
from some extra-cranial site. All of the above-mentioned scenarios warrant investigation,
which will include diagnostic imaging, due to their potentially dire consequences
Re-growth of tumour is anticipated among children with high-grade lesions, especially
glioblastomas [81, 146, 247]. However, although long-term prognoses remain dismal, small
improvements in survival times are being reported even among patients with GBMs, relating
to advanced surgical techniques, the introduction of real-time, intra-operative imaging and
brain mapping, and combining TMZ with radiation therapy [147, 189, 247-250]. Recall that in
one study in which eleven of the 20 children had either a grade III or grade IV lesion, including
two GBMs, a grade IV PNET, and a grade IV neuroblastoma, all 20 patients lived beyond four
years [35]. Nonetheless, when the return of seizures leads to the discovery of grade IV tumour
progression, surgery is almost never indicated. Instead, radiation therapy, chemotherapy, or
both can be used and may be effective at reducing seizures [81, 208]. The recurrence of seizures
does not necessarily indicate tumour progression, however. Sometimes, intrinsic changes
within the tumour itself render AEDs less effective, so that switching or combining drugs may
be beneficial [72]. As mentioned in Section 3, in such cases, care must be taken to avoid
interactions between chemotherapeutic and anti-epileptic drugs [109].
Tumour re-growth also in anticipated in many low-grade gliomas and other neuroglial
tumours when total resection is not achieved, and this can be manifested by the recurrence or
worsening of seizures. This being said, malignant transformation has been documented with
virtually every form of low-grade brain tumour, especially low-grade gliomas [65, 68, 112,
131], but also traditionally-benign lesions like DNETS [64, 67, 209-211], gangliogliomas [209,
212], meningiomas [251, 252], vestibular schwannomas [251], pituitary adenomas [251], and
haemangioblastomas [251], among others. Glioblastomas have even been documented to arise
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at the site of previously totally-resected tumours [253]. Previously-controlled seizures
generally are harder to control once malignant-transformation has occurred, even independent
of tumour size or rate of progression [78]. Identification of such transformation therefore has
implications in terms of patient prognosis, and management of both the tumour and the
seizures.
Finally, the late recurrence of seizures can represent the formation of a secondary tumour,
perhaps induced by brain irradiation or chemotherapy [251].
5.2. Surgical management of persistent and recurrent seizures
Whether seizures start immediately after surgery, later along in follow-up, or never fully remit,
in all three scenarios, some patients will have seizures that remain uncontrolled despite the
use of AEDs. In our review of the 26 studies listed in Table 2, as well as in various other case
series and case studies, we found that, occasionally, patients undergo second or even third
resections to remove either residual tumour that is now identified on post-operative imaging,
or a residual or newly-identified epileptogenic focus. Though sometimes prolonged attempts
are made to control the seizures with medication prior to the second surgery, in some cases,
surgery is almost immediate, even within a few days of the initial procedure [254]. In one multi-
centre survey that involved 116 children under age 3 undergoing epilepsy surgery for a variety
of causes, 27 children were brought into the operating room for a second procedure, and six
of these for a third procedure to control seizures [171]. Both the approaches and results of these
second operations are mixed. In terms of the former, attempts are usually made to resect any
residual or newly-discovered tumour, as well as to identify and resect other epileptogenic foci.
Approaches range from simple lesionectomies to lobectomies and, in the most severe cases,
hemispherectomies [243].
Table 5 summarizes ten studies we identified, published over the past two decades, in which
second operative procedures were performed [46, 77, 157, 1 [6]2, 171, 216, 242, 254-256]. Half of
these studies were exclusive to paediatric patients, while the other half included children,
adolescents and adults. The study by Steinbok et al. was restricted to infants under the age of
3 years at the time of their initial surgery [171]. In this study, six of the patients required a third
surgical procedure prior to achieving their final seizure outcome. Follow-up for most of these
studies was approximately two years, but sometimes not reported. Overall, slightly less than
half of the patients (46%) achieved seizure freedom, with roughly half the remainder (where
reported) achieving at least a significant reduction in seizures. As with the first procedures,
operative mortality was low, with only one death in 132 patients and 138 procedures.
6. Conclusions
A brain tumour is identified in one to three percent of non-febrile seizures that occur in a child.
Meanwhile, seizures occur in between one in ten and one in five paediatric patients with a
brain tumour, often as a presenting symptom. Most are associated with low-grade gliomas,
like pilocytic astrocytoma, or with neuroglial tumours like ganglioglioma or dysembryoplastic
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neuroectodermal tumour (DNET). There is no empirical justification for initiating an anti-
epileptic drug in a brain tumour patient without seizures, and some would restrict their use
to those patients who experience at least two ictal episodes.
The cornerstone of management in most patients with a low-grade lesion is surgical resection,
both because doing so often prolongs survival and reduces or eliminates seizures. Overall,
almost 80% of children who undergo surgery to for resection of an epileptogenic brain tumour
will attain prolonged seizure-freedom, and more than 90% will experience at least some
meaningful clinical improvement, associated with a negligible risk of death in experienced
surgical hands. Risks may be greater and results poorer in very small infants (under one year
of age), but most-preschool children can undergo epilepsy-lesion resections safely and with
benefit. Significant surgical complications occur in 10-20% of patients and include fluid and
electrolyte imbalances, as well as typically short-lived neurological deficits in most patients,
so that vigilant post-operative monitoring is essential.
Late post-operative seizure recurrence is an ominous sign that can be a harbinger of tumour
recurrence, progression, or malignant transformation, as well as the appearance of new
tumours, especially in patients with familial tumour syndromes like neurofibromatosis and
tuberous sclerosis, and those who have received brain irradiation. When low-grade tumours
recur and cause seizures, second resections may be effective at again controlling seizures.
These claims must be interpreted with caution, however, given that many essential questions
remain unanswered — like whether more extensive epilepsy surgery is more effective or as
safe as lesionectomy alone; and what factors best predict outcomes. In addition, with the
emergence of new anti-epileptics, new anti-neoplastic treatments, and new surgical technol‐
ogies, the management of epilepsy in children and adolescents with brain tumours appears to
be rapidly changing.
AED Interactions with
Phenytoin carboplain, cisplatin, cyclophosphamide, dacarbazine, erlotinib, etoposide, fluorouracil,
ifosfamide, imatanib, irinotecan, carmustine, lomustine, paclitaxel,
procarbazine, tegafur, teniposide, thiotepa, topotecan, vincristine
Carbamazepine cisplatin, cyclophosphamide, erlotinib, etoposide, ifosfamide, imatinib, irinotecan,
carmustine, lomustine, palitaxel, procarbazine*, teniposide, thiotepa, topotecan, vincristine
Phenobarbitol cyclophosphamide, erlotinib, etoposide, ifosfamide, imatinib, irinotecan, carmustine,
lomustine, paclitaxel, procarbazine, teniposide, thiotepa, topotecan, vincristine
Primidone cyclophosphamide, erlotinib, etoposide, ifosfamide, imatinib, irinotecan, carmustine,
lomustine, paclitaxel, procarbazine, teniposide, thiotepa, topotecan, vincristine
Valproic Acid cisplatin, cyclophosphamide, vorinostat
*Carbamazepine is contraindicated in patients on procarbazine
Table 1. Anti-epileptic drugs (AED) and their interactions with CNS anti-neoplastic drugs
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* Some patients died before final seizure assessment; ** Three patients underwent a second reaction; *** These 16 pa‐
tients part of a larger series with other seizure aetiologies included
GG=ganglioglioma; DNET=dysembryoplastic neuroepithelial tumor; PGNT=papillary glioneuronal tumor; LGG=low-
grade glioma; ODG=oliogodendroglioma; AC=astrocytoma; CPP=choroid plexus papilloma; CP=craniopharyngioma;
L=lesionectomy; L+E=lesionectomy+additional resection of adjacent epileptogenic tissue; L+A=lesionectomy+amygdy‐
lohypocampectomy; L+L=lesionectomy+lobectomy; TL=temporal lobectomy; L+L+A=lesionectomy+lobectomy+amyg‐
dylohypocampectomy; AHC=amygdylohypocampectomy; (T)=all temporal lesions
Table 2. Seizure response to surgical resection of epileptogenic tumor
Table 3. Seizure response to surgical resection of dysembroplastic neuroectodermal tumors
Vasc=vascular lesions; SEGA=subependymal cell astrocytoma; TS=tuberous sclerosis; FU=follow-up
Table 4. Seizure response to surgical resection of epileptogenic tumor – studies including vascular lesions
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First Year # Mean #
Author Published Subjects Age (y)* Seizure Free
Benifla 2006 12 13.5 7
Chae 2001 1 0.3 1
Gonzalez-Martinez 2007 57 24.7 22
Im 2002 3 16.5 3
Jooma 1995 8 24.0 5
Lombardi 1997 1 ? 1
Ojemann 2012 4 8.5 2
Steinbok 2009 24 1.5 12
Tian 2011 9 13.7 3
Whittle 1995 4 36.0 0
Totals 123 56
Mean 15.4
Percentages 45.5%
Table 5. Seizure response to a second surgical resection
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